常山药业：2025年度业绩预告

Group 1 - The core point of the article is that Changshan Pharmaceutical (300255) has announced an expected net profit attributable to shareholders for the year 2025, ranging from -285 million to -190 million yuan, compared to -249.48 million yuan in the same period last year [1] Group 2 - The company anticipates a significant loss in 2025, indicating a worsening financial outlook compared to the previous year [1] - The projected net profit range reflects a potential increase in losses, highlighting ongoing challenges faced by the company [1] - The announcement may impact investor sentiment and market perception of the company's financial health [1]